ANNOUNCEMENT

Take a look at the MedCity ENGAGE program, with expert speakers from leading organizations. Reserve your place today.

Cleveland Clinic names Eric Klein as chairman of Glickman Institute

February 5, 2009 9:40 pm by | 4 Comments

Dr. Eric Klein, Cleveland Clinic

Dr. Eric Klein

CLEVELAND, Ohio — The Cleveland Clinic has named Dr. Eric Klein as chairman of its Glickman Urological and Kidney institute.

Klein succeeds his longtime mentor, Dr. Andrew Novick, who died from complications of cancer in October.

Klein is a leader in the biology and management of prostate cancer. His clinical interest is the study of urologic cancers, including those of the prostate, bladder, testis and kidney. He also is well regarded for his reconstructive surgeries.

“As a national and international expert in his field, Eric is well-positioned to further expand the institute’s reputation for medical and surgical advancements while fostering an environment of collaboration,” said Dr. Joseph Hahn, Cleveland Clinic chief of staff, in a written statement.

Klein had been interim chairman of the Glickman Institute since the untimely passing of Novick.

“I’m humbled and honored to be able to lead such a distinguished group of people who are truly committed to uncovering new, innovative treatments and delivering the best outcomes for our patients,” Klein said in the statement.

Copyright 2013 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Mary Vanac

By Mary Vanac

Mary Vanac is a co-founder of MedCity News.
More posts by Author

2 comments
June Berkey
June Berkey

My brother who is 62 has been dx with agreesive prostate cancer He lives in Rittman, Ohio. I live in Fla. and Dr Yore highly recommended Dr. Klein. My question as we need fast action is does the Wooster Office have high skilled people do this surgrey in Wooster or does he need to come to Cleveland?.

Stay Up To Date

Recent Comments

Research Center

Jobs Board

Next Story
Akron Children’s to get greater access to cystic fibrosis drugs, clinical trials
Close